Literature DB >> 8980783

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.

M G Cormican1, R N Jones.   

Abstract

Compound LB20304 is a fluoronaphthyridone carboxylic acid with a novel pyrrolidine substituent. This drug was compared with ciprofloxacin, levofloxacin, ofloxacin, and trovafloxacin against over 800 pathogens, most from blood stream infections, by National Committee for Clinical Laboratory Standards reference methods. LB20304 was the most active agent against gram-positive species including strains observed to be resistant to other fluoroquinolones and glycopeptides. The potency of LB20304 (MIC50, 0.03 micrograms/ml) against the Enterobacteriaceae was exceeded only by that of ciprofloxacin (0.015 micrograms/ml). It has limited activity against gram-negative anaerobes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8980783      PMCID: PMC163688     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.

Authors:  J I Oh; K S Paek; M J Ahn; M Y Kim; C Y Hong; I C Kim; J H Kwak
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

Authors:  T D Gootz; K E Brighty; M R Anderson; B J Schmieder; S L Haskell; J A Sutcliffe; M J Castaldi; P R McGuirk
Journal:  Diagn Microbiol Infect Dis       Date:  1994-08       Impact factor: 2.803

3.  The in-vitro activity of a new highly active quinolone, DU-6859a.

Authors:  A Jolley; J M Andrews; N Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

Review 4.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

5.  Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

Authors:  R N Jones; E N Kehrberg; M E Erwin; S C Anderson
Journal:  Diagn Microbiol Infect Dis       Date:  1994-08       Impact factor: 2.803

Review 6.  Hospital-acquired infections: diseases with increasingly limited therapies.

Authors:  M N Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

  6 in total
  23 in total

1.  Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.

Authors:  V J Heaton; C E Goldsmith; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.

Authors:  D Hardy; D Amsterdam; L A Mandell; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  N Kleinkauf; G Ackermann; R Schaumann; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Antipneumococcal activities of gemifloxacin compared to those of nine other agents.

Authors:  T A Davies; L M Kelly; G A Pankuch; K L Credito; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

6.  Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 7.  The development of new antimicrobial agents.

Authors:  R Wise
Journal:  BMJ       Date:  1998-09-05

8.  Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group.

Authors:  M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

9.  Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.

Authors:  A Allen; E Bygate; M Vousden; S Oliver; M Johnson; C Ward; A Cheon; Y S Choo; I Kim
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

10.  Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  T A Davies; L M Kelly; D B Hoellman; L M Ednie; C L Clark; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.